Efficacy and safety of ultra-low-dose Vagifem (10 mcg)

Patient Preference and Adherence

Volumn 5, Issue , 2011, Pages 571-574

  Chollet, Janet A ^a,b  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b Pear Tree Pharmaceuticals   (United States)

Author keywords

Estradiol; Menopause; Vulvovaginal atrophy

Indexed keywords

ESTRADIOL; PLACEBO;

ARTICLE; BACKACHE; DIARRHEA; DOSE RESPONSE; DRUG ABSORPTION; DRUG APPROVAL; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; DRUG USE; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; ESTROGEN THERAPY; HUMAN; LOW DRUG DOSE; MENOPAUSE; RISK ASSESSMENT; TABLET FORMULATION; TREATMENT DURATION; TREATMENT RESPONSE; VAGINA ATROPHY; VAGINA MYCOSIS; VULVA PRURITUS;

EID: 84859050028     PISSN: None     EISSN: 1177889X     Source Type: Journal    
DOI: 10.2147/PPA.S22940     Document Type: Article

References (17)

1. Wolters Kluwer. Standard Population Data. 2008. Available at: http:// www.wolterskluwer.com. Accessed November 8, 2011.
2. North American Menopause Society. The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women: 2007 position statement of the North American Menopausal Society. Menopause. 2007;14(3 Pt 1):355-369.
3. Shulman LP, Portman DJ, Lee WC, et al. A retrospective managed care claims data analysis of medication adherence to vaginal estrogen therapy: implications for clinical practice. J Womens Health (Larchmt). 2008;17(4):569-578.
4. Nilsson K, Heimer G. Low-dose oestradiol in the treatment of urogenital oestrogen deficiency-a pharmacokinectic and pharmacodynamics study. Maturitas. 1992;15(2):121-127.
5. Mainini G, Scaffa C, Rotondi M, Messalli EM, Quirino L, Ragucci A. Local estrogen replacement therapy in postmenopausal atrophic vaginitis: efficacy and safety of low-dose 17b-estradiol vaginal tablets. Clin Exp Obstet Gynecol. 2005;32(2):111-113.
6. Rioux JE, Devlin C, Gelfand MM, Steinburg WM, Hepburn DS. 17b-estradiol vaginal tablet versus conjugated equine estrogen vaginal cream to relieve menopausal atrophic vaginitis. Menopause. 2000; 7(3):156-161.
7. Dugal R, Hesla K, Sørdal T, Aase KH, Lilleeidet O, Wickstrøm E. Comparison of usefulness of estradiol vaginal tablets and estriol vagitories for treatment of vaginal atrophy. Acta Obstet Gynecol Scand. 2000;79:292-297.
8. Simunić V, Banović I, Ciglar S, Jeren L, Pavicić Baldani D, Sprem M. Local estrogen treatment in patients with urogenital symptoms. Int J Gynaecol Obstet. 2003;82(2):187-197.
9. Notelovitz M, Funk S, Nanavati N, Mazzeo N. Estradiol absorption from vaginal tablets in postmenopausal women. Obstet Gynecol. 2002;99(4):556-562.
10. Bachmann G, Rogerio A, Gut R, Nachtigall L, Notelovitz M. Efficacy of low-dose estradiol vaginal tablets in the treatment of atrophic vaginitis: a randomized controlled trial. Obstet Gynecol. 2008;111(1): 67-76.
11. Simon J, Nachtigall L, Gut R, Lang E, Archer D, Utian W. Effective treatment of vaginal atrophy with an ultra-low-dose estradiol vaginal tablet. Obstet Gynecol. 2008;112(5):1053-1060.
12. Ulrich LS, Naessen T, Elia D, Goldstein JA, Eugster-Hausmann M; VAG-1748 trial investigators. Endometrial safety of ultra-low-dose Vagifen 10 mcg in postmenopausal women with vaginal atrophy. Climacteric. 2010;13(3):228-237.
13. Simon J, Nachtigall L, Ulrich LG, Eugster-Hausmann M, Gut R. Endometrial safety of ultra-low-dose estradiol vaginal tablets. Obstet Gynecol. 2010;116(4):876-883.
14. Notelovitz M, Funk S, Nanavati N, Mazzeo N. Estradiol absorption from vaginal tablets in postmenopausal women. Obstet Gynecol. 2002; 99(4):556-562.
15. Eugster-Hausmann M, Waitzinger J, Lehnick D. Minimized estradiol absorption with ultra-low-dose 10 microg 17beta-estradiol vaginal tablets. Climacteric. 2010;13(3):219-227.
16. Mayo Clinic. A Trial to Evaluate the Efficacy of Low Dose Vaginal Estrogens in the Treatment of Atrophic Vaginitis. In: ClinicalTrials. gov [Internet]. Bethesda, MD: National Library of Medicine (US). 2008. Available from: http://clinicaltrials.gov/ct2/show/NCT00816556. NLM Identifier: NCT00816556.
17. Novo Nordisk. Vagifem 10 mcg to replace Vagifem 25 mcg formulation for atrophic vaginitis due to menopause. Available at: http://press. novonordisk-us.com/index.php?s=43&item=252. Accessed October 7, 2010.